nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—UGT1A1—hematologic cancer	0.138	0.803	CbGaD
Naproxen—Ibuprofen—Procarbazine—hematologic cancer	0.126	0.656	CrCrCtD
Naproxen—migraine—Prednisone—hematologic cancer	0.101	0.508	CpDpCtD
Naproxen—osteoarthritis—Prednisone—hematologic cancer	0.098	0.492	CpDpCtD
Naproxen—Ibuprofen—Melphalan—hematologic cancer	0.0663	0.344	CrCrCtD
Naproxen—ALB—hematologic cancer	0.0338	0.197	CbGaD
Naproxen—SLCO1A2—Chlorambucil—hematologic cancer	0.0169	0.0631	CbGbCtD
Naproxen—PTGS2—Lenalidomide—hematologic cancer	0.0168	0.0624	CbGbCtD
Naproxen—AKR1C3—Doxorubicin—hematologic cancer	0.0158	0.0589	CbGbCtD
Naproxen—UGT1A1—Nilotinib—hematologic cancer	0.0114	0.0423	CbGbCtD
Naproxen—UGT2B7—Epirubicin—hematologic cancer	0.0093	0.0346	CbGbCtD
Naproxen—CYP1A2—Anagrelide—hematologic cancer	0.00912	0.0339	CbGbCtD
Naproxen—PTGS2—Thalidomide—hematologic cancer	0.00895	0.0333	CbGbCtD
Naproxen—PTGS1—Bortezomib—hematologic cancer	0.00867	0.0323	CbGbCtD
Naproxen—UGT1A1—Irinotecan—hematologic cancer	0.00782	0.0291	CbGbCtD
Naproxen—PTGS1—Thalidomide—hematologic cancer	0.00756	0.0281	CbGbCtD
Naproxen—PTGS1—Ifosfamide—hematologic cancer	0.00665	0.0248	CbGbCtD
Naproxen—SLCO1A2—Prednisolone—hematologic cancer	0.00641	0.0239	CbGbCtD
Naproxen—PTGS1—Imatinib—hematologic cancer	0.00635	0.0237	CbGbCtD
Naproxen—UGT1A1—Etoposide—hematologic cancer	0.00626	0.0233	CbGbCtD
Naproxen—PTGS2—Triamcinolone—hematologic cancer	0.0062	0.0231	CbGbCtD
Naproxen—SLCO1A2—Prednisone—hematologic cancer	0.00605	0.0225	CbGbCtD
Naproxen—CYP2C9—Bexarotene—hematologic cancer	0.0057	0.0212	CbGbCtD
Naproxen—PTGS2—Betamethasone—hematologic cancer	0.00532	0.0198	CbGbCtD
Naproxen—CYP2C8—Bortezomib—hematologic cancer	0.00501	0.0186	CbGbCtD
Naproxen—CYP1A2—Carmustine—hematologic cancer	0.00479	0.0178	CbGbCtD
Naproxen—ALB—Imatinib—hematologic cancer	0.00475	0.0177	CbGbCtD
Naproxen—CYP2C9—Idarubicin—hematologic cancer	0.00472	0.0176	CbGbCtD
Naproxen—CYP1A2—Methoxsalen—hematologic cancer	0.00407	0.0152	CbGbCtD
Naproxen—CYP1A2—Bortezomib—hematologic cancer	0.00387	0.0144	CbGbCtD
Naproxen—CYP2C8—Ifosfamide—hematologic cancer	0.00384	0.0143	CbGbCtD
Naproxen—PTGS2—Cisplatin—hematologic cancer	0.00383	0.0143	CbGbCtD
Naproxen—SLCO1A2—Dexamethasone—hematologic cancer	0.00378	0.0141	CbGbCtD
Naproxen—PTGS2—Etoposide—hematologic cancer	0.00376	0.014	CbGbCtD
Naproxen—CYP1A2—Daunorubicin—hematologic cancer	0.00371	0.0138	CbGbCtD
Naproxen—CYP1A2—Alitretinoin—hematologic cancer	0.00363	0.0135	CbGbCtD
Naproxen—CYP2C9—Bortezomib—hematologic cancer	0.00349	0.013	CbGbCtD
Naproxen—CYP1A2—Thalidomide—hematologic cancer	0.00338	0.0126	CbGbCtD
Naproxen—CYP2C8—Nilotinib—hematologic cancer	0.00333	0.0124	CbGbCtD
Naproxen—PTGS1—Etoposide—hematologic cancer	0.00318	0.0118	CbGbCtD
Naproxen—ALB—Prednisone—hematologic cancer	0.00313	0.0116	CbGbCtD
Naproxen—PTGS2—Dexamethasone—hematologic cancer	0.0031	0.0115	CbGbCtD
Naproxen—CYP2C9—Thalidomide—hematologic cancer	0.00304	0.0113	CbGbCtD
Naproxen—SLCO1A2—Methotrexate—hematologic cancer	0.00304	0.0113	CbGbCtD
Naproxen—ALB—Irinotecan—hematologic cancer	0.00296	0.011	CbGbCtD
Naproxen—CYP1A2—Dacarbazine—hematologic cancer	0.0029	0.0108	CbGbCtD
Naproxen—CYP2C9—Teniposide—hematologic cancer	0.0029	0.0108	CbGbCtD
Naproxen—CYP1A2—Imatinib—hematologic cancer	0.00284	0.0106	CbGbCtD
Naproxen—CYP2C9—Ifosfamide—hematologic cancer	0.00268	0.00997	CbGbCtD
Naproxen—CYP2C9—Imatinib—hematologic cancer	0.00256	0.00952	CbGbCtD
Naproxen—CYP2C9—Nilotinib—hematologic cancer	0.00232	0.00865	CbGbCtD
Naproxen—CYP1A2—Dasatinib—hematologic cancer	0.00228	0.00849	CbGbCtD
Naproxen—PTGS2—ovarian follicle—hematologic cancer	0.00205	0.194	CbGeAlD
Naproxen—SLC22A6—Methotrexate—hematologic cancer	0.00184	0.00686	CbGbCtD
Naproxen—CYP2C8—Etoposide—hematologic cancer	0.00183	0.00683	CbGbCtD
Naproxen—ALB—Methotrexate—hematologic cancer	0.00157	0.00584	CbGbCtD
Naproxen—CYP2C8—Dexamethasone—hematologic cancer	0.00151	0.00561	CbGbCtD
Naproxen—CYP1A2—Etoposide—hematologic cancer	0.00142	0.00529	CbGbCtD
Naproxen—CYP2C9—Cisplatin—hematologic cancer	0.0013	0.00485	CbGbCtD
Naproxen—CYP2C9—Dexamethasone—hematologic cancer	0.00105	0.00392	CbGbCtD
Naproxen—UGT1A1—hematopoietic system—hematologic cancer	0.000674	0.0639	CbGeAlD
Naproxen—AKR1C3—blood—hematologic cancer	0.000484	0.0459	CbGeAlD
Naproxen—AKR1C3—bone marrow—hematologic cancer	0.000469	0.0444	CbGeAlD
Naproxen—SLCO1A2—hematopoietic system—hematologic cancer	0.000457	0.0433	CbGeAlD
Naproxen—UGT1A1—blood—hematologic cancer	0.000447	0.0423	CbGeAlD
Naproxen—UGT2B7—testis—hematologic cancer	0.000435	0.0412	CbGeAlD
Naproxen—AKR1C3—lung—hematologic cancer	0.000425	0.0402	CbGeAlD
Naproxen—AKR1C3—testis—hematologic cancer	0.000401	0.038	CbGeAlD
Naproxen—AKR1C3—Podofilox—Teniposide—hematologic cancer	0.000377	0.235	CbGdCrCtD
Naproxen—CYP2C8—hematopoietic system—hematologic cancer	0.000319	0.0302	CbGeAlD
Naproxen—CYP1A2—hematopoietic system—hematologic cancer	0.000299	0.0283	CbGeAlD
Naproxen—Nabumetone—MPO—hematologic cancer	0.000295	0.198	CrCbGaD
Naproxen—AKR1C3—lymph node—hematologic cancer	0.00029	0.0275	CbGeAlD
Naproxen—CYP2C9—hematopoietic system—hematologic cancer	0.000283	0.0268	CbGeAlD
Naproxen—SLCO1A2—lung—hematologic cancer	0.000265	0.0251	CbGeAlD
Naproxen—PTGS1—hematopoietic system—hematologic cancer	0.000259	0.0245	CbGeAlD
Naproxen—SLCO1A2—testis—hematologic cancer	0.00025	0.0237	CbGeAlD
Naproxen—ALB—testis—hematologic cancer	0.000249	0.0236	CbGeAlD
Naproxen—PTGS2—hematopoietic system—hematologic cancer	0.000247	0.0234	CbGeAlD
Naproxen—AKR1C3—Vincristine—Vinorelbine—hematologic cancer	0.00024	0.15	CbGdCrCtD
Naproxen—Suprofen—UGT1A1—hematologic cancer	0.000237	0.159	CrCbGaD
Naproxen—AKR1C3—Podofilox—Etoposide—hematologic cancer	0.000224	0.14	CbGdCrCtD
Naproxen—CYP2C8—blood—hematologic cancer	0.000211	0.02	CbGeAlD
Naproxen—CYP1A2—blood—hematologic cancer	0.000198	0.0187	CbGeAlD
Naproxen—AKR1C3—Vinblastine—Vinorelbine—hematologic cancer	0.000193	0.12	CbGdCrCtD
Naproxen—AKR1C3—Vincristine—Vinblastine—hematologic cancer	0.000192	0.12	CbGdCrCtD
Naproxen—CYP2C9—blood—hematologic cancer	0.000188	0.0178	CbGeAlD
Naproxen—ALB—lymph node—hematologic cancer	0.00018	0.0171	CbGeAlD
Naproxen—CYP2C8—testis—hematologic cancer	0.000175	0.0166	CbGeAlD
Naproxen—Indomethacin—ABCC3—hematologic cancer	0.000174	0.117	CrCbGaD
Naproxen—CYP1A2—lung—hematologic cancer	0.000173	0.0164	CbGeAlD
Naproxen—PTGS1—blood—hematologic cancer	0.000171	0.0162	CbGeAlD
Naproxen—PTGS2—blood—hematologic cancer	0.000164	0.0155	CbGeAlD
Naproxen—PTGS2—bone marrow—hematologic cancer	0.000159	0.015	CbGeAlD
Naproxen—AKR1C3—Vinblastine—Vincristine—hematologic cancer	0.000154	0.0962	CbGdCrCtD
Naproxen—Indomethacin—UGT1A1—hematologic cancer	0.000151	0.101	CrCbGaD
Naproxen—PTGS1—lung—hematologic cancer	0.00015	0.0142	CbGeAlD
Naproxen—PTGS2—lung—hematologic cancer	0.000144	0.0136	CbGeAlD
Naproxen—PTGS1—testis—hematologic cancer	0.000142	0.0134	CbGeAlD
Naproxen—Ibuprofen—BCL2—hematologic cancer	0.000139	0.0937	CrCbGaD
Naproxen—Flurbiprofen—UGT1A1—hematologic cancer	0.000133	0.0894	CrCbGaD
Naproxen—Ibuprofen—UGT1A1—hematologic cancer	0.000119	0.0797	CrCbGaD
Naproxen—PTGS1—lymph node—hematologic cancer	0.000103	0.00974	CbGeAlD
Naproxen—PTGS2—lymph node—hematologic cancer	9.82e-05	0.00931	CbGeAlD
Naproxen—Fenoprofen—ALB—hematologic cancer	5e-05	0.0336	CrCbGaD
Naproxen—PTGS2—Fluocinonide—Dexamethasone—hematologic cancer	4.67e-05	0.0291	CbGdCrCtD
Naproxen—PTGS2—Fluocinonide—Betamethasone—hematologic cancer	4.67e-05	0.0291	CbGdCrCtD
Naproxen—PTGS2—Fluocinonide—Triamcinolone—hematologic cancer	4.56e-05	0.0285	CbGdCrCtD
Naproxen—Indomethacin—ALB—hematologic cancer	3.69e-05	0.0248	CrCbGaD
Naproxen—Indomethacin—ABCB1—hematologic cancer	3.52e-05	0.0237	CrCbGaD
Naproxen—Flurbiprofen—ALB—hematologic cancer	3.26e-05	0.0219	CrCbGaD
Naproxen—Ketoprofen—ALB—hematologic cancer	2.95e-05	0.0198	CrCbGaD
Naproxen—Ibuprofen—ALB—hematologic cancer	2.91e-05	0.0195	CrCbGaD
Naproxen—PTGS2—Fluticasone Propionate—Betamethasone—hematologic cancer	2.82e-05	0.0176	CbGdCrCtD
Naproxen—PTGS2—Fluticasone Propionate—Dexamethasone—hematologic cancer	2.82e-05	0.0176	CbGdCrCtD
Naproxen—Ibuprofen—ABCB1—hematologic cancer	2.77e-05	0.0186	CrCbGaD
Naproxen—PTGS2—Fluticasone Propionate—Triamcinolone—hematologic cancer	2.75e-05	0.0172	CbGdCrCtD
Naproxen—Ill-defined disorder—Methotrexate—hematologic cancer	5.77e-06	4.83e-05	CcSEcCtD
Naproxen—Tinnitus—Doxorubicin—hematologic cancer	5.77e-06	4.82e-05	CcSEcCtD
Naproxen—Anaemia—Methotrexate—hematologic cancer	5.75e-06	4.81e-05	CcSEcCtD
Naproxen—Feeling abnormal—Betamethasone—hematologic cancer	5.75e-06	4.81e-05	CcSEcCtD
Naproxen—Feeling abnormal—Dexamethasone—hematologic cancer	5.75e-06	4.81e-05	CcSEcCtD
Naproxen—Cardiac disorder—Doxorubicin—hematologic cancer	5.74e-06	4.8e-05	CcSEcCtD
Naproxen—Flatulence—Epirubicin—hematologic cancer	5.74e-06	4.8e-05	CcSEcCtD
Naproxen—Tension—Epirubicin—hematologic cancer	5.71e-06	4.78e-05	CcSEcCtD
Naproxen—Gastrointestinal pain—Dexamethasone—hematologic cancer	5.7e-06	4.77e-05	CcSEcCtD
Naproxen—Gastrointestinal pain—Betamethasone—hematologic cancer	5.7e-06	4.77e-05	CcSEcCtD
Naproxen—Hypersensitivity—Triamcinolone—hematologic cancer	5.66e-06	4.74e-05	CcSEcCtD
Naproxen—Nervousness—Epirubicin—hematologic cancer	5.65e-06	4.73e-05	CcSEcCtD
Naproxen—Angiopathy—Doxorubicin—hematologic cancer	5.61e-06	4.69e-05	CcSEcCtD
Naproxen—Malaise—Methotrexate—hematologic cancer	5.61e-06	4.69e-05	CcSEcCtD
Naproxen—Dizziness—Etoposide—hematologic cancer	5.61e-06	4.69e-05	CcSEcCtD
Naproxen—Muscle spasms—Epirubicin—hematologic cancer	5.6e-06	4.68e-05	CcSEcCtD
Naproxen—Immune system disorder—Doxorubicin—hematologic cancer	5.59e-06	4.67e-05	CcSEcCtD
Naproxen—Vertigo—Methotrexate—hematologic cancer	5.59e-06	4.67e-05	CcSEcCtD
Naproxen—Mediastinal disorder—Doxorubicin—hematologic cancer	5.58e-06	4.66e-05	CcSEcCtD
Naproxen—Leukopenia—Methotrexate—hematologic cancer	5.57e-06	4.66e-05	CcSEcCtD
Naproxen—Chills—Doxorubicin—hematologic cancer	5.55e-06	4.64e-05	CcSEcCtD
Naproxen—Urticaria—Betamethasone—hematologic cancer	5.54e-06	4.63e-05	CcSEcCtD
Naproxen—Urticaria—Dexamethasone—hematologic cancer	5.54e-06	4.63e-05	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Prednisone—hematologic cancer	5.54e-06	4.63e-05	CcSEcCtD
Naproxen—Dizziness—Prednisolone—hematologic cancer	5.53e-06	4.62e-05	CcSEcCtD
Naproxen—Arrhythmia—Doxorubicin—hematologic cancer	5.53e-06	4.62e-05	CcSEcCtD
Naproxen—Asthenia—Triamcinolone—hematologic cancer	5.52e-06	4.61e-05	CcSEcCtD
Naproxen—Body temperature increased—Dexamethasone—hematologic cancer	5.51e-06	4.61e-05	CcSEcCtD
Naproxen—Abdominal pain—Dexamethasone—hematologic cancer	5.51e-06	4.61e-05	CcSEcCtD
Naproxen—Body temperature increased—Betamethasone—hematologic cancer	5.51e-06	4.61e-05	CcSEcCtD
Naproxen—Abdominal pain—Betamethasone—hematologic cancer	5.51e-06	4.61e-05	CcSEcCtD
Naproxen—Nausea—Cisplatin—hematologic cancer	5.5e-06	4.6e-05	CcSEcCtD
Naproxen—Insomnia—Prednisone—hematologic cancer	5.5e-06	4.59e-05	CcSEcCtD
Naproxen—Vision blurred—Epirubicin—hematologic cancer	5.49e-06	4.59e-05	CcSEcCtD
Naproxen—Alopecia—Doxorubicin—hematologic cancer	5.47e-06	4.57e-05	CcSEcCtD
Naproxen—Paraesthesia—Prednisone—hematologic cancer	5.46e-06	4.56e-05	CcSEcCtD
Naproxen—Pruritus—Triamcinolone—hematologic cancer	5.44e-06	4.55e-05	CcSEcCtD
Naproxen—Cough—Methotrexate—hematologic cancer	5.43e-06	4.54e-05	CcSEcCtD
Naproxen—Mental disorder—Doxorubicin—hematologic cancer	5.42e-06	4.53e-05	CcSEcCtD
Naproxen—Ill-defined disorder—Epirubicin—hematologic cancer	5.4e-06	4.52e-05	CcSEcCtD
Naproxen—Convulsion—Methotrexate—hematologic cancer	5.39e-06	4.51e-05	CcSEcCtD
Naproxen—Vomiting—Etoposide—hematologic cancer	5.39e-06	4.51e-05	CcSEcCtD
Naproxen—Erythema—Doxorubicin—hematologic cancer	5.39e-06	4.5e-05	CcSEcCtD
Naproxen—Malnutrition—Doxorubicin—hematologic cancer	5.39e-06	4.5e-05	CcSEcCtD
Naproxen—Anaemia—Epirubicin—hematologic cancer	5.38e-06	4.5e-05	CcSEcCtD
Naproxen—Dyspepsia—Prednisone—hematologic cancer	5.35e-06	4.47e-05	CcSEcCtD
Naproxen—Rash—Etoposide—hematologic cancer	5.34e-06	4.47e-05	CcSEcCtD
Naproxen—Dermatitis—Etoposide—hematologic cancer	5.34e-06	4.46e-05	CcSEcCtD
Naproxen—Headache—Etoposide—hematologic cancer	5.31e-06	4.44e-05	CcSEcCtD
Naproxen—Flatulence—Doxorubicin—hematologic cancer	5.31e-06	4.44e-05	CcSEcCtD
Naproxen—Chest pain—Methotrexate—hematologic cancer	5.3e-06	4.43e-05	CcSEcCtD
Naproxen—Arthralgia—Methotrexate—hematologic cancer	5.3e-06	4.43e-05	CcSEcCtD
Naproxen—Myalgia—Methotrexate—hematologic cancer	5.3e-06	4.43e-05	CcSEcCtD
Naproxen—Tension—Doxorubicin—hematologic cancer	5.29e-06	4.42e-05	CcSEcCtD
Naproxen—Decreased appetite—Prednisone—hematologic cancer	5.28e-06	4.42e-05	CcSEcCtD
Naproxen—Rash—Prednisolone—hematologic cancer	5.27e-06	4.41e-05	CcSEcCtD
Naproxen—Dermatitis—Prednisolone—hematologic cancer	5.27e-06	4.4e-05	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	5.26e-06	4.4e-05	CcSEcCtD
Naproxen—Malaise—Epirubicin—hematologic cancer	5.25e-06	4.39e-05	CcSEcCtD
Naproxen—Fatigue—Prednisone—hematologic cancer	5.24e-06	4.38e-05	CcSEcCtD
Naproxen—Headache—Prednisolone—hematologic cancer	5.24e-06	4.38e-05	CcSEcCtD
Naproxen—Discomfort—Methotrexate—hematologic cancer	5.23e-06	4.38e-05	CcSEcCtD
Naproxen—Nervousness—Doxorubicin—hematologic cancer	5.23e-06	4.37e-05	CcSEcCtD
Naproxen—Vertigo—Epirubicin—hematologic cancer	5.23e-06	4.37e-05	CcSEcCtD
Naproxen—Syncope—Epirubicin—hematologic cancer	5.22e-06	4.37e-05	CcSEcCtD
Naproxen—Leukopenia—Epirubicin—hematologic cancer	5.21e-06	4.36e-05	CcSEcCtD
Naproxen—Constipation—Prednisone—hematologic cancer	5.2e-06	4.34e-05	CcSEcCtD
Naproxen—Muscle spasms—Doxorubicin—hematologic cancer	5.18e-06	4.33e-05	CcSEcCtD
Naproxen—Palpitations—Epirubicin—hematologic cancer	5.15e-06	4.3e-05	CcSEcCtD
Naproxen—Confusional state—Methotrexate—hematologic cancer	5.12e-06	4.28e-05	CcSEcCtD
Naproxen—Loss of consciousness—Epirubicin—hematologic cancer	5.12e-06	4.28e-05	CcSEcCtD
Naproxen—Dizziness—Triamcinolone—hematologic cancer	5.08e-06	4.25e-05	CcSEcCtD
Naproxen—Cough—Epirubicin—hematologic cancer	5.08e-06	4.25e-05	CcSEcCtD
Naproxen—Anaphylactic shock—Methotrexate—hematologic cancer	5.08e-06	4.25e-05	CcSEcCtD
Naproxen—Vision blurred—Doxorubicin—hematologic cancer	5.08e-06	4.24e-05	CcSEcCtD
Naproxen—Convulsion—Epirubicin—hematologic cancer	5.04e-06	4.22e-05	CcSEcCtD
Naproxen—Infection—Methotrexate—hematologic cancer	5.04e-06	4.22e-05	CcSEcCtD
Naproxen—Nausea—Etoposide—hematologic cancer	5.04e-06	4.21e-05	CcSEcCtD
Naproxen—Hypertension—Epirubicin—hematologic cancer	5.03e-06	4.2e-05	CcSEcCtD
Naproxen—Feeling abnormal—Prednisone—hematologic cancer	5.01e-06	4.19e-05	CcSEcCtD
Naproxen—Asthenia—Betamethasone—hematologic cancer	5.01e-06	4.19e-05	CcSEcCtD
Naproxen—Asthenia—Dexamethasone—hematologic cancer	5.01e-06	4.19e-05	CcSEcCtD
Naproxen—Ill-defined disorder—Doxorubicin—hematologic cancer	5e-06	4.18e-05	CcSEcCtD
Naproxen—Nervous system disorder—Methotrexate—hematologic cancer	4.98e-06	4.16e-05	CcSEcCtD
Naproxen—Anaemia—Doxorubicin—hematologic cancer	4.98e-06	4.16e-05	CcSEcCtD
Naproxen—Thrombocytopenia—Methotrexate—hematologic cancer	4.97e-06	4.16e-05	CcSEcCtD
Naproxen—Gastrointestinal pain—Prednisone—hematologic cancer	4.97e-06	4.15e-05	CcSEcCtD
Naproxen—Nausea—Prednisolone—hematologic cancer	4.97e-06	4.15e-05	CcSEcCtD
Naproxen—Chest pain—Epirubicin—hematologic cancer	4.96e-06	4.14e-05	CcSEcCtD
Naproxen—Myalgia—Epirubicin—hematologic cancer	4.96e-06	4.14e-05	CcSEcCtD
Naproxen—Arthralgia—Epirubicin—hematologic cancer	4.96e-06	4.14e-05	CcSEcCtD
Naproxen—Anxiety—Epirubicin—hematologic cancer	4.94e-06	4.13e-05	CcSEcCtD
Naproxen—Pruritus—Betamethasone—hematologic cancer	4.94e-06	4.13e-05	CcSEcCtD
Naproxen—Pruritus—Dexamethasone—hematologic cancer	4.94e-06	4.13e-05	CcSEcCtD
Naproxen—Skin disorder—Methotrexate—hematologic cancer	4.93e-06	4.12e-05	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	4.92e-06	4.12e-05	CcSEcCtD
Naproxen—Hyperhidrosis—Methotrexate—hematologic cancer	4.91e-06	4.1e-05	CcSEcCtD
Naproxen—Discomfort—Epirubicin—hematologic cancer	4.9e-06	4.09e-05	CcSEcCtD
Naproxen—Vomiting—Triamcinolone—hematologic cancer	4.89e-06	4.09e-05	CcSEcCtD
Naproxen—Malaise—Doxorubicin—hematologic cancer	4.86e-06	4.06e-05	CcSEcCtD
Naproxen—Rash—Triamcinolone—hematologic cancer	4.85e-06	4.05e-05	CcSEcCtD
Naproxen—Dry mouth—Epirubicin—hematologic cancer	4.85e-06	4.05e-05	CcSEcCtD
Naproxen—Dermatitis—Triamcinolone—hematologic cancer	4.84e-06	4.05e-05	CcSEcCtD
Naproxen—Vertigo—Doxorubicin—hematologic cancer	4.84e-06	4.05e-05	CcSEcCtD
Naproxen—Anorexia—Methotrexate—hematologic cancer	4.84e-06	4.05e-05	CcSEcCtD
Naproxen—Syncope—Doxorubicin—hematologic cancer	4.83e-06	4.04e-05	CcSEcCtD
Naproxen—Urticaria—Prednisone—hematologic cancer	4.83e-06	4.04e-05	CcSEcCtD
Naproxen—Leukopenia—Doxorubicin—hematologic cancer	4.82e-06	4.03e-05	CcSEcCtD
Naproxen—Headache—Triamcinolone—hematologic cancer	4.82e-06	4.03e-05	CcSEcCtD
Naproxen—Abdominal pain—Prednisone—hematologic cancer	4.8e-06	4.02e-05	CcSEcCtD
Naproxen—Body temperature increased—Prednisone—hematologic cancer	4.8e-06	4.02e-05	CcSEcCtD
Naproxen—Confusional state—Epirubicin—hematologic cancer	4.79e-06	4.01e-05	CcSEcCtD
Naproxen—Diarrhoea—Dexamethasone—hematologic cancer	4.77e-06	3.99e-05	CcSEcCtD
Naproxen—Diarrhoea—Betamethasone—hematologic cancer	4.77e-06	3.99e-05	CcSEcCtD
Naproxen—Palpitations—Doxorubicin—hematologic cancer	4.76e-06	3.98e-05	CcSEcCtD
Naproxen—Anaphylactic shock—Epirubicin—hematologic cancer	4.75e-06	3.97e-05	CcSEcCtD
Naproxen—Oedema—Epirubicin—hematologic cancer	4.75e-06	3.97e-05	CcSEcCtD
Naproxen—Hypotension—Methotrexate—hematologic cancer	4.74e-06	3.97e-05	CcSEcCtD
Naproxen—Loss of consciousness—Doxorubicin—hematologic cancer	4.73e-06	3.96e-05	CcSEcCtD
Naproxen—Infection—Epirubicin—hematologic cancer	4.72e-06	3.95e-05	CcSEcCtD
Naproxen—Cough—Doxorubicin—hematologic cancer	4.7e-06	3.93e-05	CcSEcCtD
Naproxen—Shock—Epirubicin—hematologic cancer	4.67e-06	3.91e-05	CcSEcCtD
Naproxen—Convulsion—Doxorubicin—hematologic cancer	4.67e-06	3.9e-05	CcSEcCtD
Naproxen—Nervous system disorder—Epirubicin—hematologic cancer	4.66e-06	3.9e-05	CcSEcCtD
Naproxen—Thrombocytopenia—Epirubicin—hematologic cancer	4.65e-06	3.89e-05	CcSEcCtD
Naproxen—Hypertension—Doxorubicin—hematologic cancer	4.65e-06	3.89e-05	CcSEcCtD
Naproxen—Tachycardia—Epirubicin—hematologic cancer	4.64e-06	3.88e-05	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Methotrexate—hematologic cancer	4.63e-06	3.87e-05	CcSEcCtD
Naproxen—Skin disorder—Epirubicin—hematologic cancer	4.62e-06	3.86e-05	CcSEcCtD
Naproxen—Dizziness—Dexamethasone—hematologic cancer	4.61e-06	3.86e-05	CcSEcCtD
Naproxen—Dizziness—Betamethasone—hematologic cancer	4.61e-06	3.86e-05	CcSEcCtD
Naproxen—Hyperhidrosis—Epirubicin—hematologic cancer	4.59e-06	3.84e-05	CcSEcCtD
Naproxen—Insomnia—Methotrexate—hematologic cancer	4.59e-06	3.84e-05	CcSEcCtD
Naproxen—Myalgia—Doxorubicin—hematologic cancer	4.59e-06	3.83e-05	CcSEcCtD
Naproxen—Chest pain—Doxorubicin—hematologic cancer	4.59e-06	3.83e-05	CcSEcCtD
Naproxen—Arthralgia—Doxorubicin—hematologic cancer	4.59e-06	3.83e-05	CcSEcCtD
Naproxen—Anxiety—Doxorubicin—hematologic cancer	4.57e-06	3.82e-05	CcSEcCtD
Naproxen—Nausea—Triamcinolone—hematologic cancer	4.57e-06	3.82e-05	CcSEcCtD
Naproxen—Paraesthesia—Methotrexate—hematologic cancer	4.56e-06	3.81e-05	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	4.55e-06	3.81e-05	CcSEcCtD
Naproxen—Discomfort—Doxorubicin—hematologic cancer	4.53e-06	3.79e-05	CcSEcCtD
Naproxen—Anorexia—Epirubicin—hematologic cancer	4.53e-06	3.79e-05	CcSEcCtD
Naproxen—Dyspnoea—Methotrexate—hematologic cancer	4.53e-06	3.78e-05	CcSEcCtD
Naproxen—Somnolence—Methotrexate—hematologic cancer	4.51e-06	3.77e-05	CcSEcCtD
Naproxen—Dry mouth—Doxorubicin—hematologic cancer	4.49e-06	3.75e-05	CcSEcCtD
Naproxen—Hypersensitivity—Prednisone—hematologic cancer	4.48e-06	3.74e-05	CcSEcCtD
Naproxen—Dyspepsia—Methotrexate—hematologic cancer	4.47e-06	3.74e-05	CcSEcCtD
Naproxen—Hypotension—Epirubicin—hematologic cancer	4.44e-06	3.71e-05	CcSEcCtD
Naproxen—Vomiting—Dexamethasone—hematologic cancer	4.44e-06	3.71e-05	CcSEcCtD
Naproxen—Vomiting—Betamethasone—hematologic cancer	4.44e-06	3.71e-05	CcSEcCtD
Naproxen—Confusional state—Doxorubicin—hematologic cancer	4.43e-06	3.71e-05	CcSEcCtD
Naproxen—Decreased appetite—Methotrexate—hematologic cancer	4.41e-06	3.69e-05	CcSEcCtD
Naproxen—Rash—Dexamethasone—hematologic cancer	4.4e-06	3.68e-05	CcSEcCtD
Naproxen—Rash—Betamethasone—hematologic cancer	4.4e-06	3.68e-05	CcSEcCtD
Naproxen—Oedema—Doxorubicin—hematologic cancer	4.4e-06	3.68e-05	CcSEcCtD
Naproxen—Anaphylactic shock—Doxorubicin—hematologic cancer	4.4e-06	3.68e-05	CcSEcCtD
Naproxen—Dermatitis—Betamethasone—hematologic cancer	4.39e-06	3.67e-05	CcSEcCtD
Naproxen—Dermatitis—Dexamethasone—hematologic cancer	4.39e-06	3.67e-05	CcSEcCtD
Naproxen—Gastrointestinal disorder—Methotrexate—hematologic cancer	4.38e-06	3.67e-05	CcSEcCtD
Naproxen—Fatigue—Methotrexate—hematologic cancer	4.38e-06	3.66e-05	CcSEcCtD
Naproxen—Headache—Dexamethasone—hematologic cancer	4.37e-06	3.65e-05	CcSEcCtD
Naproxen—Headache—Betamethasone—hematologic cancer	4.37e-06	3.65e-05	CcSEcCtD
Naproxen—Infection—Doxorubicin—hematologic cancer	4.37e-06	3.65e-05	CcSEcCtD
Naproxen—Asthenia—Prednisone—hematologic cancer	4.36e-06	3.64e-05	CcSEcCtD
Naproxen—Pain—Methotrexate—hematologic cancer	4.34e-06	3.63e-05	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Epirubicin—hematologic cancer	4.33e-06	3.62e-05	CcSEcCtD
Naproxen—Shock—Doxorubicin—hematologic cancer	4.33e-06	3.62e-05	CcSEcCtD
Naproxen—Nervous system disorder—Doxorubicin—hematologic cancer	4.31e-06	3.61e-05	CcSEcCtD
Naproxen—Thrombocytopenia—Doxorubicin—hematologic cancer	4.3e-06	3.6e-05	CcSEcCtD
Naproxen—Pruritus—Prednisone—hematologic cancer	4.3e-06	3.59e-05	CcSEcCtD
Naproxen—Insomnia—Epirubicin—hematologic cancer	4.3e-06	3.59e-05	CcSEcCtD
Naproxen—Tachycardia—Doxorubicin—hematologic cancer	4.29e-06	3.59e-05	CcSEcCtD
Naproxen—Skin disorder—Doxorubicin—hematologic cancer	4.27e-06	3.57e-05	CcSEcCtD
Naproxen—Paraesthesia—Epirubicin—hematologic cancer	4.27e-06	3.57e-05	CcSEcCtD
Naproxen—Hyperhidrosis—Doxorubicin—hematologic cancer	4.25e-06	3.55e-05	CcSEcCtD
Naproxen—Dyspnoea—Epirubicin—hematologic cancer	4.24e-06	3.54e-05	CcSEcCtD
Naproxen—Somnolence—Epirubicin—hematologic cancer	4.22e-06	3.53e-05	CcSEcCtD
Naproxen—Anorexia—Doxorubicin—hematologic cancer	4.19e-06	3.5e-05	CcSEcCtD
Naproxen—Feeling abnormal—Methotrexate—hematologic cancer	4.18e-06	3.5e-05	CcSEcCtD
Naproxen—Dyspepsia—Epirubicin—hematologic cancer	4.18e-06	3.5e-05	CcSEcCtD
Naproxen—Diarrhoea—Prednisone—hematologic cancer	4.16e-06	3.48e-05	CcSEcCtD
Naproxen—Gastrointestinal pain—Methotrexate—hematologic cancer	4.15e-06	3.47e-05	CcSEcCtD
Naproxen—Nausea—Dexamethasone—hematologic cancer	4.14e-06	3.46e-05	CcSEcCtD
Naproxen—Nausea—Betamethasone—hematologic cancer	4.14e-06	3.46e-05	CcSEcCtD
Naproxen—Decreased appetite—Epirubicin—hematologic cancer	4.13e-06	3.45e-05	CcSEcCtD
Naproxen—Hypotension—Doxorubicin—hematologic cancer	4.11e-06	3.43e-05	CcSEcCtD
Naproxen—Gastrointestinal disorder—Epirubicin—hematologic cancer	4.1e-06	3.43e-05	CcSEcCtD
Naproxen—Fatigue—Epirubicin—hematologic cancer	4.1e-06	3.43e-05	CcSEcCtD
Naproxen—Pain—Epirubicin—hematologic cancer	4.06e-06	3.4e-05	CcSEcCtD
Naproxen—Constipation—Epirubicin—hematologic cancer	4.06e-06	3.4e-05	CcSEcCtD
Naproxen—Urticaria—Methotrexate—hematologic cancer	4.03e-06	3.37e-05	CcSEcCtD
Naproxen—Dizziness—Prednisone—hematologic cancer	4.02e-06	3.36e-05	CcSEcCtD
Naproxen—Body temperature increased—Methotrexate—hematologic cancer	4.01e-06	3.36e-05	CcSEcCtD
Naproxen—Abdominal pain—Methotrexate—hematologic cancer	4.01e-06	3.36e-05	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.01e-06	3.35e-05	CcSEcCtD
Naproxen—Insomnia—Doxorubicin—hematologic cancer	3.98e-06	3.32e-05	CcSEcCtD
Naproxen—Paraesthesia—Doxorubicin—hematologic cancer	3.95e-06	3.3e-05	CcSEcCtD
Naproxen—Dyspnoea—Doxorubicin—hematologic cancer	3.92e-06	3.28e-05	CcSEcCtD
Naproxen—Feeling abnormal—Epirubicin—hematologic cancer	3.92e-06	3.27e-05	CcSEcCtD
Naproxen—Somnolence—Doxorubicin—hematologic cancer	3.91e-06	3.27e-05	CcSEcCtD
Naproxen—Gastrointestinal pain—Epirubicin—hematologic cancer	3.89e-06	3.25e-05	CcSEcCtD
Naproxen—Dyspepsia—Doxorubicin—hematologic cancer	3.87e-06	3.24e-05	CcSEcCtD
Naproxen—Vomiting—Prednisone—hematologic cancer	3.86e-06	3.23e-05	CcSEcCtD
Naproxen—Rash—Prednisone—hematologic cancer	3.83e-06	3.2e-05	CcSEcCtD
Naproxen—Dermatitis—Prednisone—hematologic cancer	3.83e-06	3.2e-05	CcSEcCtD
Naproxen—Decreased appetite—Doxorubicin—hematologic cancer	3.82e-06	3.2e-05	CcSEcCtD
Naproxen—Headache—Prednisone—hematologic cancer	3.81e-06	3.18e-05	CcSEcCtD
Naproxen—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.8e-06	3.17e-05	CcSEcCtD
Naproxen—Fatigue—Doxorubicin—hematologic cancer	3.79e-06	3.17e-05	CcSEcCtD
Naproxen—Urticaria—Epirubicin—hematologic cancer	3.77e-06	3.16e-05	CcSEcCtD
Naproxen—Pain—Doxorubicin—hematologic cancer	3.76e-06	3.14e-05	CcSEcCtD
Naproxen—Constipation—Doxorubicin—hematologic cancer	3.76e-06	3.14e-05	CcSEcCtD
Naproxen—Abdominal pain—Epirubicin—hematologic cancer	3.76e-06	3.14e-05	CcSEcCtD
Naproxen—Body temperature increased—Epirubicin—hematologic cancer	3.76e-06	3.14e-05	CcSEcCtD
Naproxen—Hypersensitivity—Methotrexate—hematologic cancer	3.74e-06	3.13e-05	CcSEcCtD
Naproxen—Asthenia—Methotrexate—hematologic cancer	3.64e-06	3.05e-05	CcSEcCtD
Naproxen—Feeling abnormal—Doxorubicin—hematologic cancer	3.62e-06	3.03e-05	CcSEcCtD
Naproxen—Nausea—Prednisone—hematologic cancer	3.61e-06	3.02e-05	CcSEcCtD
Naproxen—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.6e-06	3.01e-05	CcSEcCtD
Naproxen—Pruritus—Methotrexate—hematologic cancer	3.59e-06	3e-05	CcSEcCtD
Naproxen—Hypersensitivity—Epirubicin—hematologic cancer	3.5e-06	2.93e-05	CcSEcCtD
Naproxen—Urticaria—Doxorubicin—hematologic cancer	3.49e-06	2.92e-05	CcSEcCtD
Naproxen—Abdominal pain—Doxorubicin—hematologic cancer	3.48e-06	2.91e-05	CcSEcCtD
Naproxen—Body temperature increased—Doxorubicin—hematologic cancer	3.48e-06	2.91e-05	CcSEcCtD
Naproxen—Diarrhoea—Methotrexate—hematologic cancer	3.47e-06	2.9e-05	CcSEcCtD
Naproxen—Asthenia—Epirubicin—hematologic cancer	3.41e-06	2.85e-05	CcSEcCtD
Naproxen—Pruritus—Epirubicin—hematologic cancer	3.36e-06	2.81e-05	CcSEcCtD
Naproxen—Dizziness—Methotrexate—hematologic cancer	3.36e-06	2.81e-05	CcSEcCtD
Naproxen—Diarrhoea—Epirubicin—hematologic cancer	3.25e-06	2.72e-05	CcSEcCtD
Naproxen—Hypersensitivity—Doxorubicin—hematologic cancer	3.24e-06	2.71e-05	CcSEcCtD
Naproxen—Vomiting—Methotrexate—hematologic cancer	3.23e-06	2.7e-05	CcSEcCtD
Naproxen—Rash—Methotrexate—hematologic cancer	3.2e-06	2.68e-05	CcSEcCtD
Naproxen—Dermatitis—Methotrexate—hematologic cancer	3.2e-06	2.67e-05	CcSEcCtD
Naproxen—Headache—Methotrexate—hematologic cancer	3.18e-06	2.66e-05	CcSEcCtD
Naproxen—Asthenia—Doxorubicin—hematologic cancer	3.15e-06	2.64e-05	CcSEcCtD
Naproxen—Dizziness—Epirubicin—hematologic cancer	3.14e-06	2.63e-05	CcSEcCtD
Naproxen—Pruritus—Doxorubicin—hematologic cancer	3.11e-06	2.6e-05	CcSEcCtD
Naproxen—Vomiting—Epirubicin—hematologic cancer	3.02e-06	2.53e-05	CcSEcCtD
Naproxen—Nausea—Methotrexate—hematologic cancer	3.02e-06	2.52e-05	CcSEcCtD
Naproxen—Diarrhoea—Doxorubicin—hematologic cancer	3.01e-06	2.52e-05	CcSEcCtD
Naproxen—Rash—Epirubicin—hematologic cancer	3e-06	2.5e-05	CcSEcCtD
Naproxen—Dermatitis—Epirubicin—hematologic cancer	2.99e-06	2.5e-05	CcSEcCtD
Naproxen—Headache—Epirubicin—hematologic cancer	2.98e-06	2.49e-05	CcSEcCtD
Naproxen—Dizziness—Doxorubicin—hematologic cancer	2.91e-06	2.43e-05	CcSEcCtD
Naproxen—Nausea—Epirubicin—hematologic cancer	2.82e-06	2.36e-05	CcSEcCtD
Naproxen—Vomiting—Doxorubicin—hematologic cancer	2.8e-06	2.34e-05	CcSEcCtD
Naproxen—Rash—Doxorubicin—hematologic cancer	2.77e-06	2.32e-05	CcSEcCtD
Naproxen—Dermatitis—Doxorubicin—hematologic cancer	2.77e-06	2.32e-05	CcSEcCtD
Naproxen—Headache—Doxorubicin—hematologic cancer	2.75e-06	2.3e-05	CcSEcCtD
Naproxen—Nausea—Doxorubicin—hematologic cancer	2.61e-06	2.18e-05	CcSEcCtD
Naproxen—PTGS2—Disease—PRKCG—hematologic cancer	2.23e-06	6.38e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PIK3CB—hematologic cancer	2.22e-06	6.36e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—EP300—hematologic cancer	2.22e-06	6.36e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	2.2e-06	6.31e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NCOA3—hematologic cancer	2.19e-06	6.29e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ADCY7—hematologic cancer	2.19e-06	6.29e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SPHK1—hematologic cancer	2.19e-06	6.28e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	2.19e-06	6.27e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NUP214—hematologic cancer	2.18e-06	6.25e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—MTHFR—hematologic cancer	2.17e-06	6.24e-05	CbGpPWpGaD
Naproxen—AKR1C3—Disease—HRAS—hematologic cancer	2.17e-06	6.21e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	2.16e-06	6.19e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.16e-06	6.18e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SRC—hematologic cancer	2.15e-06	6.18e-05	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—AKT1—hematologic cancer	2.14e-06	6.14e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—MTR—hematologic cancer	2.13e-06	6.12e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ABCG2—hematologic cancer	2.13e-06	6.12e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GSTP1—hematologic cancer	2.12e-06	6.1e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PIK3CB—hematologic cancer	2.11e-06	6.06e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CD—hematologic cancer	2.11e-06	6.06e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—UGT1A1—hematologic cancer	2.1e-06	6.03e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—VEGFA—hematologic cancer	2.1e-06	6.02e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ENO2—hematologic cancer	2.09e-06	6e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—ALB—hematologic cancer	2.08e-06	5.98e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—STAT3—hematologic cancer	2.08e-06	5.96e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CREBBP—hematologic cancer	2.08e-06	5.96e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—NQO1—hematologic cancer	2.07e-06	5.95e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CD44—hematologic cancer	2.07e-06	5.95e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—NRAS—hematologic cancer	2.07e-06	5.95e-05	CbGpPWpGaD
Naproxen—AKR1C3—Disease—IL6—hematologic cancer	2.07e-06	5.95e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—NQO1—hematologic cancer	2.06e-06	5.91e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—CD44—hematologic cancer	2.06e-06	5.91e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MTHFR—hematologic cancer	2.06e-06	5.91e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.06e-06	5.9e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—TERT—hematologic cancer	2.05e-06	5.9e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—HLA-A—hematologic cancer	2.05e-06	5.9e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CRABP1—hematologic cancer	2.05e-06	5.87e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SLC22A1—hematologic cancer	2.05e-06	5.87e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—IL2—hematologic cancer	2.04e-06	5.84e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTT1—hematologic cancer	2.03e-06	5.82e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	2.03e-06	5.82e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	2.02e-06	5.79e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ABCB1—hematologic cancer	2.01e-06	5.77e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PDGFB—hematologic cancer	2.01e-06	5.75e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	2e-06	5.73e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ALOX5—hematologic cancer	1.99e-06	5.72e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3R1—hematologic cancer	1.99e-06	5.72e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MAPK3—hematologic cancer	1.98e-06	5.69e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—SDC1—hematologic cancer	1.98e-06	5.69e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CD—hematologic cancer	1.97e-06	5.65e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYCS—hematologic cancer	1.96e-06	5.63e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—TSC2—hematologic cancer	1.96e-06	5.62e-05	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PIK3CA—hematologic cancer	1.96e-06	5.62e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GSTM1—hematologic cancer	1.95e-06	5.6e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—NCOR1—hematologic cancer	1.95e-06	5.6e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYCS—hematologic cancer	1.95e-06	5.6e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—HSP90AA1—hematologic cancer	1.95e-06	5.59e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—ALB—hematologic cancer	1.94e-06	5.58e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—HSP90AA1—hematologic cancer	1.94e-06	5.56e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NUP98—hematologic cancer	1.93e-06	5.54e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MYC—hematologic cancer	1.93e-06	5.54e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TGFB1—hematologic cancer	1.93e-06	5.53e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.92e-06	5.5e-05	CbGpPWpGaD
Naproxen—AKR1C3—Disease—AKT1—hematologic cancer	1.91e-06	5.49e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.9e-06	5.44e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—FGFR3—hematologic cancer	1.89e-06	5.41e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ADCY7—hematologic cancer	1.87e-06	5.38e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NCOA3—hematologic cancer	1.87e-06	5.38e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	1.87e-06	5.37e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NUP214—hematologic cancer	1.86e-06	5.34e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3R1—hematologic cancer	1.86e-06	5.34e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	1.84e-06	5.29e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CB—hematologic cancer	1.84e-06	5.28e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—EP300—hematologic cancer	1.83e-06	5.24e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CG—hematologic cancer	1.83e-06	5.24e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTEN—hematologic cancer	1.83e-06	5.24e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—MTR—hematologic cancer	1.82e-06	5.23e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ABCG2—hematologic cancer	1.82e-06	5.23e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.79e-06	5.13e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ENO2—hematologic cancer	1.79e-06	5.13e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—BAD—hematologic cancer	1.79e-06	5.13e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—KRAS—hematologic cancer	1.78e-06	5.12e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—SRC—hematologic cancer	1.78e-06	5.1e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—NOTCH1—hematologic cancer	1.77e-06	5.08e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.75e-06	5.03e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.74e-06	5e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—EP300—hematologic cancer	1.74e-06	4.99e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTT1—hematologic cancer	1.73e-06	4.98e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CD80—hematologic cancer	1.73e-06	4.98e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—KIT—hematologic cancer	1.73e-06	4.97e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—VEGFA—hematologic cancer	1.73e-06	4.96e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTP1—hematologic cancer	1.73e-06	4.96e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—MTHFR—hematologic cancer	1.73e-06	4.95e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTP1—hematologic cancer	1.72e-06	4.93e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CB—hematologic cancer	1.72e-06	4.93e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—NRAS—hematologic cancer	1.71e-06	4.9e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.71e-06	4.9e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PTPN11—hematologic cancer	1.7e-06	4.88e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SDC1—hematologic cancer	1.7e-06	4.86e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CREBBP—hematologic cancer	1.69e-06	4.86e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CD44—hematologic cancer	1.69e-06	4.84e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NQO1—hematologic cancer	1.69e-06	4.84e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.67e-06	4.8e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.66e-06	4.77e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.65e-06	4.74e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CREB1—hematologic cancer	1.65e-06	4.73e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PIK3CA—hematologic cancer	1.64e-06	4.7e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—MAPK3—hematologic cancer	1.64e-06	4.7e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ABCB1—hematologic cancer	1.64e-06	4.7e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—BRAF—hematologic cancer	1.63e-06	4.67e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—ABCB1—hematologic cancer	1.63e-06	4.67e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.62e-06	4.65e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—IL6R—hematologic cancer	1.61e-06	4.61e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CD—hematologic cancer	1.61e-06	4.61e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CREBBP—hematologic cancer	1.61e-06	4.61e-05	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—AKT1—hematologic cancer	1.6e-06	4.59e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	1.6e-06	4.59e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYCS—hematologic cancer	1.6e-06	4.58e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTEN—hematologic cancer	1.59e-06	4.56e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTM1—hematologic cancer	1.59e-06	4.56e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—NCOR1—hematologic cancer	1.59e-06	4.56e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TGFB1—hematologic cancer	1.59e-06	4.56e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	1.59e-06	4.55e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TP53—hematologic cancer	1.59e-06	4.55e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—ALB—hematologic cancer	1.58e-06	4.55e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—NCOR1—hematologic cancer	1.58e-06	4.53e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTM1—hematologic cancer	1.58e-06	4.53e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MAP2K1—hematologic cancer	1.53e-06	4.4e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.53e-06	4.39e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CD—hematologic cancer	1.52e-06	4.37e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.52e-06	4.36e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—HRAS—hematologic cancer	1.52e-06	4.35e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3R1—hematologic cancer	1.52e-06	4.35e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—EP300—hematologic cancer	1.52e-06	4.35e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTEN—hematologic cancer	1.48e-06	4.26e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—KRAS—hematologic cancer	1.47e-06	4.22e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—FGF2—hematologic cancer	1.46e-06	4.18e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL6—hematologic cancer	1.45e-06	4.16e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CG—hematologic cancer	1.45e-06	4.16e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CD44—hematologic cancer	1.44e-06	4.14e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NQO1—hematologic cancer	1.44e-06	4.14e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3R1—hematologic cancer	1.44e-06	4.12e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.43e-06	4.1e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—EP300—hematologic cancer	1.41e-06	4.06e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.41e-06	4.05e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTP1—hematologic cancer	1.41e-06	4.04e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—MTHFR—hematologic cancer	1.4e-06	4.03e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CB—hematologic cancer	1.4e-06	4.02e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—JAK2—hematologic cancer	1.4e-06	4.01e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—MTHFR—hematologic cancer	1.4e-06	4.01e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYCS—hematologic cancer	1.36e-06	3.91e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MDM2—hematologic cancer	1.36e-06	3.91e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.36e-06	3.91e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	1.36e-06	3.89e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PIK3CA—hematologic cancer	1.35e-06	3.88e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CREBBP—hematologic cancer	1.34e-06	3.86e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—AKT1—hematologic cancer	1.34e-06	3.84e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ABCB1—hematologic cancer	1.33e-06	3.82e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MTOR—hematologic cancer	1.33e-06	3.81e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CB—hematologic cancer	1.33e-06	3.81e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CD4—hematologic cancer	1.32e-06	3.8e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TP53—hematologic cancer	1.31e-06	3.75e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NCOR1—hematologic cancer	1.29e-06	3.71e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTM1—hematologic cancer	1.29e-06	3.71e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PIK3CA—hematologic cancer	1.29e-06	3.69e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CD—hematologic cancer	1.27e-06	3.66e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ALB—hematologic cancer	1.26e-06	3.61e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—HRAS—hematologic cancer	1.25e-06	3.59e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CDKN1B—hematologic cancer	1.24e-06	3.57e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.24e-06	3.55e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.23e-06	3.53e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.22e-06	3.5e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTEN—hematologic cancer	1.21e-06	3.47e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3R1—hematologic cancer	1.2e-06	3.45e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTP1—hematologic cancer	1.2e-06	3.45e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CG—hematologic cancer	1.18e-06	3.38e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CG—hematologic cancer	1.17e-06	3.37e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.16e-06	3.34e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—EP300—hematologic cancer	1.15e-06	3.31e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CDKN1A—hematologic cancer	1.15e-06	3.3e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PTEN—hematologic cancer	1.15e-06	3.29e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—MTHFR—hematologic cancer	1.14e-06	3.28e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ABCB1—hematologic cancer	1.14e-06	3.27e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CA—hematologic cancer	1.12e-06	3.22e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CB—hematologic cancer	1.11e-06	3.19e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NCOR1—hematologic cancer	1.1e-06	3.17e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTM1—hematologic cancer	1.1e-06	3.17e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—AKT1—hematologic cancer	1.1e-06	3.17e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CREBBP—hematologic cancer	1.09e-06	3.14e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—EP300—hematologic cancer	1.09e-06	3.14e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—CREBBP—hematologic cancer	1.09e-06	3.12e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—SRC—hematologic cancer	1.06e-06	3.05e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—AKT1—hematologic cancer	1.05e-06	3.02e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CA—hematologic cancer	1.05e-06	3e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CD—hematologic cancer	1.04e-06	2.98e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CD—hematologic cancer	1.03e-06	2.96e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—STAT3—hematologic cancer	1.03e-06	2.94e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ALB—hematologic cancer	1.02e-06	2.94e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—NRAS—hematologic cancer	1.02e-06	2.93e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.01e-06	2.89e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MAPK3—hematologic cancer	9.79e-07	2.81e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3R1—hematologic cancer	9.79e-07	2.81e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—MTHFR—hematologic cancer	9.76e-07	2.8e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3R1—hematologic cancer	9.74e-07	2.79e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CG—hematologic cancer	9.6e-07	2.75e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PTEN—hematologic cancer	9.6e-07	2.75e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MYC—hematologic cancer	9.53e-07	2.73e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—TGFB1—hematologic cancer	9.5e-07	2.73e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—AKT1—hematologic cancer	9.16e-07	2.63e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—EP300—hematologic cancer	9.15e-07	2.63e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CB—hematologic cancer	9.04e-07	2.59e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CB—hematologic cancer	8.99e-07	2.58e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CREBBP—hematologic cancer	8.9e-07	2.55e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—KRAS—hematologic cancer	8.8e-07	2.53e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	8.61e-07	2.47e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—AKT1—hematologic cancer	8.55e-07	2.45e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CA—hematologic cancer	8.53e-07	2.45e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CD—hematologic cancer	8.44e-07	2.42e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ALB—hematologic cancer	8.33e-07	2.39e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CG—hematologic cancer	8.2e-07	2.35e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CA—hematologic cancer	8.09e-07	2.32e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3R1—hematologic cancer	7.97e-07	2.29e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTEN—hematologic cancer	7.81e-07	2.24e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTEN—hematologic cancer	7.77e-07	2.23e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CREBBP—hematologic cancer	7.61e-07	2.18e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—HRAS—hematologic cancer	7.48e-07	2.15e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—EP300—hematologic cancer	7.45e-07	2.14e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—EP300—hematologic cancer	7.41e-07	2.13e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CB—hematologic cancer	7.36e-07	2.11e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CD—hematologic cancer	7.21e-07	2.07e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—IL6—hematologic cancer	7.16e-07	2.05e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ALB—hematologic cancer	7.12e-07	2.04e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—AKT1—hematologic cancer	6.97e-07	2e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3R1—hematologic cancer	6.81e-07	1.95e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CA—hematologic cancer	6.77e-07	1.94e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—AKT1—hematologic cancer	6.61e-07	1.9e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTEN—hematologic cancer	6.36e-07	1.82e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CB—hematologic cancer	6.29e-07	1.8e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—EP300—hematologic cancer	6.06e-07	1.74e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—AKT1—hematologic cancer	5.53e-07	1.59e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CA—hematologic cancer	5.51e-07	1.58e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CA—hematologic cancer	5.48e-07	1.57e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTEN—hematologic cancer	5.43e-07	1.56e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—EP300—hematologic cancer	5.18e-07	1.49e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—AKT1—hematologic cancer	4.5e-07	1.29e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CA—hematologic cancer	4.48e-07	1.29e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—AKT1—hematologic cancer	4.48e-07	1.28e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CA—hematologic cancer	3.83e-07	1.1e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—AKT1—hematologic cancer	3.66e-07	1.05e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—AKT1—hematologic cancer	3.13e-07	8.98e-06	CbGpPWpGaD
